BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bandrés E, Zárate R, Ramirez N, Abajo A, Bitarte N, García-Foncillas J. Pharmacogenomics in colorectal cancer: The first step for individualized-therapy. World J Gastroenterol 2007; 13(44): 5888-5901 [PMID: 17990354 DOI: 10.3748/wjg.v13.i44.5888]
URL: https://www.wjgnet.com/1007-9327/full/v13/i44/5888.htm
Number Citing Articles
1
Eugenia Ch Yiannakopoulou, Debmalya Barh. Omics Approaches in Breast Cancer2014; : 499 doi: 10.1007/978-81-322-0843-3_25
2
Martina Blaschke, Jutta Blumberg, Ulrike Wegner, Martin Nischwitz, Giuliano Ramadori, Silke Cameron. Measurements of 5-FU Plasma Concentrations in Patients with Gastrointestinal Cancer: 5-FU Levels Reflect the 5-FU Dose AppliedJournal of Cancer Therapy 2012; 3(01): 28 doi: 10.4236/jct.2012.31004
3
Álvaro Esteban Alfaro Alfaro, Brayan Murillo Castillo, Eugenia Cordero García, Javier Tascón, Ana I. Morales. Colon Cancer Pharmacogenetics: A Narrative ReviewPharmacy 2022; 10(4): 95 doi: 10.3390/pharmacy10040095
4
Scott R. Kelley, Heidi Nelson. Abeloff's Clinical Oncology2020; : 1281 doi: 10.1016/B978-0-323-47674-4.00075-X
5
Beatriz Stransky, Pedro Galante. An Omics Perspective on Cancer Research2010; : 211 doi: 10.1007/978-90-481-2675-0_12
6
Ana de la Cueva, Ana Ramírez de Molina, Néstor Álvarez-Ayerza, Ma Angeles Ramos, Arancha Cebrián, Teresa Gómez del Pulgar, Juan Carlos Lacal, Irina V. Lebedeva. Combined 5-FU and ChoKα Inhibitors as a New Alternative Therapy of Colorectal Cancer: Evidence in Human Tumor-Derived Cell Lines and Mouse XenograftsPLoS ONE 2013; 8(6): e64961 doi: 10.1371/journal.pone.0064961
7
E Ch Yiannakopoulou. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implicationsThe Pharmacogenomics Journal 2013; 13(2): 105 doi: 10.1038/tpj.2012.42
8
Chih-Ping Hsu, Chih-Cheng Lin, Chiu-Chen Huang, Yi-Hsien Lin, Jyh-Ching Chou, Yu-Ting Tsia, Jhih-Rou Su, Yuan-Chiang Chung. Induction of Apoptosis and Cell Cycle Arrest in Human Colorectal Carcinoma by Litchi Seed ExtractJournal of Biomedicine and Biotechnology 2012; 2012: 1 doi: 10.1155/2012/341479
9
Amirsaeed Sabeti Aghabozorgi, Samaneh Sharif, Reza Jafarzadeh-Esfehani, Saba Vakili, Mohammad Reza Abbaszadegan. Role of miRNA Gene Variants in the Susceptibility and Pharmacogenetics of Colorectal CancerPharmacogenomics 2021; 22(5): 303 doi: 10.2217/pgs-2020-0159
10
Amaia García-Bilbao, Rubén Armañanzas, Ziortza Ispizua, Begoña Calvo, Ana Alonso-Varona, Iñaki Inza, Pedro Larrañaga, Guillermo López-Vivanco, Blanca Suárez-Merino, Mónica Betanzos. Identification of a biomarker panel for colorectal cancer diagnosisBMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-43
11
Harshil Shah, Vivek Chavda, Moinuddin M. Soniwala. Bioinformatics Tools for Pharmaceutical Drug Product Development2023; : 95 doi: 10.1002/9781119865728.ch6
12
Yogita A. Ghodke-Puranik, Jatinder K. Lamba. Innovative Approaches in Drug Discovery2017; : 195 doi: 10.1016/B978-0-12-801814-9.00007-6
13
T. Winder, H.-J. Lenz. Praxis der Viszeralchirurgie Onkologische Chirurgie2010; : 187 doi: 10.1007/978-3-642-03808-2_17
14
Young S. Yi, Gil Alterovitz. Pathobiology of Cancer Regimen-Related Toxicities2013; : 63 doi: 10.1007/978-1-4614-5438-0_4
15
Ebrahim Eftekhar, Fakhraddin Naghibalhossaini. Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancerMolecular Biology Reports 2014; 41(1): 459 doi: 10.1007/s11033-013-2880-0
16
Hong Ma, Guilin Chen, Mingquan Guo. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancerPROTEOMICS – Clinical Applications 2016; 10(4): 503 doi: 10.1002/prca.201500082
17
Kim M Smits, Arjen HG Cleven, Matty P Weijenberg, Laura AE Hughes, James G Herman, Adriaan P de Bruïne, Manon van Engeland. Pharmacoepigenomics in Colorectal Cancer: A Step Forward in Predicting Prognosis and Treatment ResponsePharmacogenomics 2008; 9(12): 1903 doi: 10.2217/14622416.9.12.1903
18
Rhonda J. Moore. Biobehavioral Approaches to Pain2009; : 259 doi: 10.1007/978-0-387-78323-9_11
19
Hiroshi Hirata, Yuji Hinoda, Koichi Nakajima, Nobuyuki Kikuno, Yutaka Suehiro, Z. Laura Tabatabai, Nobuhisa Ishii, Rajvir Dahiya. The bcl2 −938CC Genotype Has Poor Prognosis and Lower Survival in Renal CancerJournal of Urology 2009; 182(2): 721 doi: 10.1016/j.juro.2009.03.081
20
Bo Yang, Xiande Wang, Dong Dong, Yunqing Pan, Junhua Wu, Jianjian Liu. Existing Drug Repurposing for Glioblastoma to Discover Candidate Drugs as a New a ApproachLetters in Drug Design & Discovery 2022; 19(1): 31 doi: 10.2174/1570180818666210509141735
21
A. Astier. Apports récents de la pharmacogénomique dans le traitement des cancers colorectauxAnnales Pharmaceutiques Françaises 2010; 68(4): 233 doi: 10.1016/j.pharma.2010.04.001